Sarepta Therapeutics CSO Gilmore MMSc receives $6.4M in 2018
Sarepta Therapeutics reports 2018 executive compensation
By ExecPay News
Published: April 26, 2019
Sarepta Therapeutics reported fiscal year 2018 executive compensation information on April 26, 2019.
In 2018, five executives at Sarepta Therapeutics received on average a compensation package of $3.7M, a 64% decrease compared to previous year.
Average pay of disclosed executives at Sarepta Therapeutics
Gilmore O'Neill, M.B., M.M.Sc, Chief Scientific Officer, received $6.4M in total. 74% of MMSc's compensation, or $4.8M, was in option awards. MMSc also received $213K in non-equity incentive plan, $311K in salary, $1.2M in stock awards, as well as $2.1K in other compensation.
For fiscal year 2018, the median employee pay was $329,229 at Sarepta Therapeutics. Therefore, the ratio of Gilmore O'Neill, M.B., M.M.Sc's pay to the median employee pay was 20 to one.
Sandesh Mahatme, Chief Financial Officer, received a compensation package of $4.2M, which increased by 92% compared to previous year. 80% of the compensation package, or $3.4M, was in option awards.
David Tyronne Howton, Jr, General Counsel, earned $3.1M in 2018, a 72% increase compared to previous year.
Alexander Cumbo, Executive Vice President, Chief Commercial Officer, received $3.1M in 2018, which increases by 34% compared to 2017.
Douglas Ingram, Chief Executive Officer, earned $1.4M in 2018, a 97% decrease compared to previous year.
Related executives
Douglas Ingram
Sarepta Therapeutics
Chief Executive Officer
Sandesh Mahatme
Sarepta Therapeutics
Chief Financial Officer
David Howton
Sarepta Therapeutics
General Counsel
Gilmore MMSc
Sarepta Therapeutics
Chief Scientific Officer
Alexander Cumbo
Sarepta Therapeutics
Executive Vice President, Chief Commercial Officer
You may also like
Source: SEC filing on April 26, 2019.